Find Out if You Potentially Qualify for a Financial Reward by filling out the form.
(1) Kenvue faces potential headwinds as a result of confirmed concerns about the efficacy of phenylephrine, which it knew or should have known; (2) Kenvue did not discuss risks relating to the efficacy of phenylephrine (or “PE”) in its IPO, the utility of which had been questioned since at least 2007; (3) while the Company disclosed risks relating to litigation, it did not disclose specific risk relating to potential litigation arising from adverse findings on the efficacy of phenylephrine; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared.
In order to be included in the lawsuit, you must have incurred a loss on shares of Kenvue purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.
If you suffered a loss in Kenvue during the relevant time frame or pursuant to the relevant offering(s), you have until December 08, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.